David A. Siegel Editas Medicine, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,205,000 shares of EDIT stock, worth $3.13 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,205,000
Previous 940,600
28.11%
Holding current value
$3.13 Million
Previous $2.07 Million
102.08%
% of portfolio
0.01%
Previous 0.0%
Shares
32 transactions
Others Institutions Holding EDIT
# of Institutions
223Shares Held
46.2MCall Options Held
841KPut Options Held
304K-
Black Rock Inc. New York, NY7.78MShares$20.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.97MShares$18.1 Million0.0% of portfolio
-
Nuveen, LLC Charlotte, NC2.09MShares$5.44 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.04MShares$5.3 Million0.0% of portfolio
-
State Street Corp Boston, MA1.93MShares$5.01 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $179M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...